Full-Time

Data Scientist II

Tissue Engineering

Confirmed live in the last 24 hours

Valo Health

Valo Health

51-200 employees

Drug discovery using machine learning technology

Compensation Overview

$145k - $160kAnnually

Junior, Mid

New York, NY, USA

Category
Computational Biology
Data Science
Data Analysis
Biology & Biotech
Data & Analytics
Required Skills
Python
Data Science
Neural Networks
SQL
Machine Learning
AWS
Computer Vision
Data Analysis
Snowflake
Google Cloud Platform
Requirements
  • A Ph.D., Master’s degree +2-3 years’ experience, or BS +3-4 years’ experience, in a relevant computational science field (e.g., computational biology, bioengineering, biostatistics)
  • Strong programming skills in Python and proficiency with data analysis libraries database management, as well as versioning of code, data, and models, with additional skills in SQL preferred
  • Strong background in data analysis and statistics
  • Experience with computer vision and machine learning techniques and tools, such as neural networks, generative models, regression, ensemble learning, regularization, and classification
  • Strong familiarity with bioengineering principles and human tissue models preferred
  • Familiarity with cardiovascular/metabolic/renal/immune systems in the context of computational biology also preferred
  • Excellent problem-solving and critical thinking abilities
  • Strong communication skills for effective collaboration and results presentation
  • Familiarity with Data and DS best practices; data platforms (data bricks, snowflake); cloud environments (AWS, GCP)
Responsibilities
  • Data capture and processing
  • Data pipelines, meta-data capture and provenance
  • Imaging and time series data processing
  • Collaborate with biologists and computational scientists to visualize, preprocess, and analyze large datasets related to human tissue models and bioengineering experiments
  • Create clear and informative data visualizations and statistical summaries to communicate findings to technical and non-technical colleagues
  • Implement robust validation procedures to ensure reliability and accuracy of tissue engineering and biological model data
  • Assist in planning experiments, ensuring data collection is optimized for downstream statistical and analytical purposes
  • Develop predictive models and algorithms to identify factors impacting the development, manufacturing and use of tissue models
  • Optimize experimental conditions and understand complex biological systems in pursuit of optimal drug candidates
  • Model in-vitro phenotypic responses to chemical and genetic perturbations
Desired Qualifications
  • Strong familiarity with bioengineering principles and human tissue models preferred
  • Familiarity with cardiovascular/metabolic/renal/immune systems in the context of computational biology also preferred

Valo Health focuses on drug discovery and development in the biopharmaceutical sector. The company utilizes its Opal Computational platform, which integrates machine learning, tissue biology, and patient data, to create tools that enhance the drug development process. This platform allows Valo Health to identify potential drug candidates more efficiently than traditional methods. Unlike many competitors, Valo Health combines technology with life sciences, enabling it to tackle significant challenges in the industry. The company's goal is to improve health outcomes for patients globally by delivering effective solutions through partnerships with pharmaceutical companies and research institutions.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$474.2M

Headquarters

Boston, Massachusetts

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Novo Nordisk partnership could yield up to $4.6 billion in milestone payments.
  • AI-driven drug discovery is gaining market traction, benefiting Valo's business model.
  • Valo's large human-centric data library enhances predictive drug development capabilities.

What critics are saying

  • Leadership changes may impact strategic direction and decision-making.
  • Heavy reliance on partnerships poses financial risks if milestones aren't met.
  • Competitive AI-driven drug discovery landscape challenges Valo's market position.

What makes Valo Health unique

  • Valo Health integrates AI and human data for accelerated drug discovery.
  • Opal Computational Platform™ offers a unified architecture for drug development.
  • Focus on cardiovascular, oncology, and neurodegenerative diseases sets Valo apart.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-5%

2 year growth

-8%
Valo Health
Jan 24th, 2025
Valo Health Receives $110 Million in Funding From Koch Disruptive…

Valo is a new type of technology company, uniting human and machine intelligence aiming to accelerate the creation of life-changing cures.

BioSpace
Jan 9th, 2025
Novo Puts $4.6B On The Line To Expand Valo Deal, Maintain Cardiometabolic Leadership

Novo Nordisk on Wednesday announced that it will expand a 2023 contract with Boston biotech Valo Health to develop novel treatments for obesity, type 2 diabetes and other cardiometabolic conditions.The expanded deal’s initial consideration involves a total of $190 million in an upfront payment, equity investment and milestones. The partners will be able to work collaboratively on up to 20 drug programs for which milestone payments could reach around $4.6 billion, in addition to R&D funding and potential royalties.Novo and Valo first entered into their partnership in September 2023. At the time, the obesity leader paid $60 million upfront and pledged up to $2.7 billion for the opportunity to collaborate on 11 cardiometabolic programs. At the center of the collaboration is Valo’s AI-enabled preclinical capabilities, which allow the biotech to identify and validate druggable targets, as well as design and screen potentially therapeutic molecules against these targets.Valo says its preclinical edge comes from its proprietary computational platform Opal, which leverages AI models built using high-quality human data. What the biotech calls its “integrated approach” to drug discovery and development generates and uses data at every stage of the process—from disease and target discovery through regulatory approval—producing a “self-reinforcing, active learning system” that improves its performance with each experiment, the company says on its website.Valo claims its human-centric data library is “the largest and densest in the world,” and that models developed using these data can help Valo and its partners predict disease progression “and how a drug will perform before it even touches a person.”For Novo, Valo’s approach appears to be working well. Pharma CSO Marcus Schindler said in a statement on Wednesday that the company is “very pleased with the progress” it has seen under the Valo partnership, leading to its decision to expand the agreement

Rama On Healthcare
Jan 8th, 2025
Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship's Valo Health

Novo Nordisk's collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease.

Reuters
Jan 8th, 2025
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO) and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).

Fierce Biotech
Jan 8th, 2025
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes

If the programs hit their milestones, Valo could receive $4.6 billion from Novo plus R&D funding and potential royalty payments.